Chindu Govindaraj

机构：AstraZeneca (Japan)

发表论文 25 篇 · 总被引 341 次 · h-index 7

代表论文

• Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment (2013 · Clinical Immunology · 被引 121)
• Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients (2013 · Clinical Cancer Research · 被引 82)
• Lenalidomide‐based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients (2014 · American Journal of Hematology · 被引 46)
• Maintenance lenalidomide in combination with 5‐azacitidine as post‐remission therapy for acute myeloid leukaemia (2015 · British Journal of Haematology · 被引 38)
• TNFR2 Expression on CD25hiFOXP3+ T Cells Induced upon TCR Stimulation of CD4 T Cells Identifies Maximal Cytokine-Producing Effectors (2013 · Frontiers in Immunology · 被引 28)
• Substantially Modified Ratios of Effector to Regulatory T Cells During Chemotherapy in Ovarian Cancer Patients Return to Pre-Treatment Levels at Completion: Implications for Immunotherapy (2012 · Cancers · 被引 14)